-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On August 8, Hansoh Pharma announced that its wholly-owned subsidiaries Hansson (Shanghai) Health Technology .
Under the license agreement, the licensee received an exclusive license from TiumBio to develop and commercialize TU2670 for the treatment of endometriosis and uterine fibroids and other potential indications in China, including Hong Kong, Macau and Taiw.
$5 million down payment, $5 million in technology transfer fees and potential payments of up to $164 million in development, registration and sales-based commercialization milestones
Endometriosis refers to the endometrial cells that should grow in the uterine cavi.
Uterine fibroids are a common benign tumor that occurs in the uterus, often accompanied by symptoms such as pain, menorrhagia, dysfunctional uterine bleeding, and urinary incontinence, with an incidence of about 3
TU2670 is an orally active non-peptide gonadotropin-releasing hormone (GnRH) antagonist independently developed by Tiumbio, which can bind to pituitary receptors to inhibit the secretion of gonadotropins (luteinizing hormone and follicle-stimulating hormon.
Currently, TU2670 has completed a Phase Ia clinical trial in South Korea and a Phase Ib clinical trial in Europe (German.
Headquartered in South Korea, TiumBio is an R&D-focused biopharmaceutical company dedicated to the discovery and development of innovative small molecule and biopharmaceutica.
